A €10m capital increase removes a potential funding requirement in 2015, allowing MagForce to focus on its strategy to drive uptake and acceptance of its NanoTherm nanoparticle-based therapy for cancer. In the US, MagForce has submitted a pre-submission filing for prostate cancer to the FDA as part of the process towards starting clinical trials in 2015 in this key region. In Europe, MagForce is on track to complete additional NanoActivator installations in Germany. Our rNPV is increased to €252m.

Unlock the rest of this Article in 15 seconds

or Unlock with your email

Already have an account?
Login here